The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Open accessAbstract
A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. About 30% of patients with mUC will respond to ICIs immunotherapy. Programmed death-ligand 1 (PD-L1) expression detected by immunohistochemistry seems to predict response to immune checkpoint inhibitors in patients with mUC as supported by the objective response rate (ORR) and overall survival (OS) associated with the response observed in most clinical trials. Pembrolizumab, an anti-PD-1 antibody, demonstrated better OS respective to chemotherapy in a randomized phase 3 study for second-line treatment of mUC. Nivolumab, a PD-1 antibody, also demonstrated an OS benefit when compared to controls. Atezolizumab, Durvalumab, and Avelumab antibodies targeting PD-L1 have also received approval as second-line treatments for mUC with durable response for more than 1 year in selected patients. Atezolizumab and Pembrolizumab also received approval for first-line treatment of patients that are ineligible for cisplatin. A focus on the utility of ICIs in the adjuvant or neoadjuvant setting, or as combination with chemotherapy, is the basis of some ongoing trials. The identification of a clinically useful biomarker, single or in association, to determine the optimal ICIs treatment for patients with mUC is very much needed as emphasized by the current literature. In this review, we examined relevant clinical trial results with ICIs in patients with mUC alone or as part of drug combinations; emphasis is also placed on the adjuvant and neoadjuvant setting. The current landscape of selected biomarkers of response to ICIs including anti-PD-L1 immunohistochemistry is also briefly reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“On the other hand, tumors with a higher expression of TGFβ and its receptors and lacking CD8+ TILs were non-responsive to Atezolizumab, thus supporting the hypothesis that high TGFβ expression leads to immune exclusion [80].”
BackgroundNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 5×
“The range of results is widely variable and shows a strong association with overall response, as is the case with Durvalumab using a PD-L1 biomarker evaluated using the required composite analysis for patient selection [24] (Table 3) to no association, as noticed with Atezolizumab as secondline therapy in an IMvigor C…”
BackgroundMethodInfluentialPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.010 · Cited by 2,514 · cited 1×
“Bladder cancer is considered one of the most aggressive neoplasms worldwide [1].”
BackgroundComprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · cited 2×
“2 mutations per megabase) compared to quartiles 1 to 3 [17].”
BackgroundMethodAdjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869 · cited 1×
“6% in high PD-L1 expressing patients (TC or IC ≥ 25%) [34,35].”
BackgroundMassard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30230-0 · Cited by 786
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590 · cited 1×
“The activity of Avelumab in platinum refractory metastatic bladder cancer has been explored in the single-arm phase 1b JAVELIN clinical trial [36].”
BackgroundApolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544 · cited 1×
“Indeed, it was strongly associated with response to anti PD-1 and anti PD-L1 agents and survival outcome in patients with mUC treated with Nivolumab and Atezolizumab [76,77].”
BackgroundSharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J.-L., De Giorgi, U., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30541-6 · Cited by 501
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Bellmunt, J., Powles, T., & Vogelzang, N. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.007 · Cited by 374
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Bellmunt, J., Mullane, S. A., Werner, L., Fay, A. P., Callea, M., Leow, J. J., Taplin, M. E., Choueiri, T. K., Hodi, F. S., Freeman, G. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv009 · Cited by 276
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 243
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule, P., Smithy, J. W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., & Rimm, D. L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3015 · Cited by 201
Biomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D. H., & Drake, C. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0299-1 · Cited by 187
Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
Faraj, S. F., Munari, E., Guner, G., Taube, J., Anders, R., Hicks, J., Meeker, A., Schoenberg, M., Bivalacqua, T., Drake, C., et al. (2015) · Urology · doi:10.1016/j.urology.2014.10.020 · Cited by 178
Targeting the CD73-adenosine axis in immuno-oncology
Allard, D., Chrobak, P., Allard, B., Messaoudi, N., & Stagg, J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 158
Apolo, A. B., Nadal, R., Girardi, D. M., Niglio, S. A., Ley, L., Cordes, L. M., Steinberg, S. M., Ortiz, O. S., Cadena, J., Diaz, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01652 · Cited by 143
PD-L1 assessment in urothelial carcinoma: a practical approach
Eckstein, M., Cimadamore, A., Hartmann, A., Antonio Lopez-beltran, B., Liang Cheng, C., Scarpelli, M., Montironi, R., & Gevaert, T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.24 · Cited by 127
Self-citationGalsky, M. D., Wang, H., Hahn, N. M., Twardowski, P. W., Pal, S. K., Albany, C., Fleming, M. T., Starodub, A., Hauke, R. J., Yu, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.12.001 · Cited by 122
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 120
Oing, C., Rink, M., Oechsle, K., Seidel, C. A., Amsberg, G. V., & Bokemeyer, C. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.115 · Cited by 113
Eckstein, M., Erben, P., KRIEGMAIR, M. C., Worst, T. S., Weiss, C. A., Wirtz, R. M., Wach, S., Stoehr, R., Sikic, D., Geppert, C. I., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.007 · Cited by 110
Immune checkpoint inhibitors for metastatic bladder cancer
Massari, F., Nunno, V. D., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., Liang Cheng, C., Antonio Lopez-beltran, B., Battelli, N., & Ardizzoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.007 · Cited by 107
Self-citationHodgson, A., Slodkowska, E. A., Jungbluth, A. A., Liu, S. K., Vesprini, D., Enepekides, D., Higgins, K. M., Katabi, N., Xu, B., & Downes, M. R. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001084 · Cited by 105
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Powles, T. B., Walker, J., Williams, J. A., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101925 · Cited by 97
Reis, H., Serrette, R., Posada, J., Lu, V., Chen, Y., Gopalan, A., Fine, S. W., Tickoo, S. K., Sirintrapun, S. J., Iyer, G., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001264 · Cited by 96
Jamal, S., Hudson, M., Fifi-Mah, A. V., & Ye, C. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190084 · Cited by 91
Powles, T. B., Rodríguez‐Vida, A., Durán, I., Crabb, S. J., Heijden, M. S. V. D., Pous, A. F., Gravis, G., Herranz, U. A., Protheroe, A. S., Ravaud, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4506 · Cited by 90
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Rouanne, M., Bajorin, D. F., Hannan, R., Galsky, M. D., Williams, S. B., Necchi, A., Sharma, P., & Powles, T. B. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.06.009 · Cited by 89
Vidotto, T., Nersesian, S., Graham, C. H., Siemens, D. R., & Koti, M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0619-8 · Cited by 85
Powles, T. B., O’Donnell, P. H., Massard, C., Arkenau, H., Friedlander, T. W., Hoimes, C., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.286 · Cited by 68
Kato, R., Hayashi, H., Chiba, Y., Miyawaki, E., Shimizu, J., Ozaki, T., Fujimoto, D., Toyozawa, R., Nakamura, A., Kozuki, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000350 · Cited by 68
de Liaño, A. G., van Dijk, N., de Velasco, G., Necchi, A., Lavaud, P., Morales‐Barrera, R., Gordoa, T. A., Maroto, P., Ravaud, A., Durán, I., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.004 · Cited by 61
Bednova, O., & Leyton, J. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197268 · Cited by 58
Correale, P., Vecchio, M. T. D., Placa, M. L., Montagnani, F., Genova, G. D., Savellini, G. G., Terrosi, C., Mannucci, S., Giorgi, G., Francini, G., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815b69c8 · Cited by 56
PD-L1 Antibody Comparison in Urothelial Carcinoma
Rijnders, M., van der Veldt, A. A. M., Zuiverloon, T. C. M., Grünberg, K., Thunnissen, E., de Wit, R., & van Leenders, G. J. L. H. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.002 · Cited by 56
Powles, T. B., Gschwend, J. E., Loriot, Y., Joaquim Bellmunt, B., Géczi, L., Vulsteke, C., Abdelsalam, M. G. A., Gafanov, R. A., Bae, W. K., Révész, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps4590 · Cited by 48
Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
Zibelman, M. R., Ramamurthy, C., & Plimack, E. R. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.017 · Cited by 46
Tp53 and its potential therapeutic role as a target in bladder cancer
Ciccarese, C., Massari, F., Blanca, A., Tortora, G., Montironi, R., Cheng, L., Scarpelli, M., Raspollini, M. R., Vau, N., Fonseca, J., et al. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1297798 · Cited by 42
Self-citationIdentification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene Sets
Tang, C., Ma, J., Liu, X., & Liu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.544610 · Cited by 40
Inherited Forms of Bladder Cancer: A Review of Lynch Syndrome and Other Inherited Conditions
Phelan, A., López-Beltrán, A., Montironi, R., Zhang, S., Raspollini, M. R., Cheng, M., Kaimakliotis, H. Z., Koch, M. O., & Cheng, L. (2018) · Future Oncology · doi:10.2217/fon-2017-0346 · Cited by 34
Self-citationAdjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies
Massari, F., Santoni, M., Nunno, V. D., Liang Cheng, C., Antonio Lopez-beltran, B., Cimadamore, A., Gasparrini, S., Scarpelli, M., Battelli, N., & Montironi, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.002 · Cited by 29
Self-citationRoviello, G., Catalano, M., Nobili, S., Santi, R., Mini, E., & Nesi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217935 · Cited by 27
Cimadamore, A., Gasparrini, S., Santoni, M., Liang Cheng, C., Antonio Lopez-beltran, B., Battelli, N., Massari, F., Giunchi, F., Fiorentino, M., Scarpelli, M., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1490179 · Cited by 25
Self-citationImmunotherapy and urothelial carcinoma: An overview and future prospectives
Pierantoni, F., Maruzzo, M., Gardi, M., Bezzon, E., Gardiman, M. P., Porreca, A., Basso, U., & Zagonel, V. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.08.005 · Cited by 22
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
Gevaert, T., Montironi, R., Antonio Lopez-beltran, B., van Leenders, G., Allory, Y., Ridder, D. J. M. K. D., Claessens, F., Kockx, M. M., Akand, M., Joniau, S., et al. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.004 · Cited by 17
Self-citationCiccarese, C., Iacovelli, R., Bria, E., Mosillo, C., Bimbatti, D., Fantinel, E., Bisogno, I., Brunelli, M., & Tortora, G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.01.001 · Cited by 17
Narits, J., Tamm, H., & Jaal, J. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.003 · Cited by 17
Gevaert, T., Cimadamore, A., Eckstein, M., Scarpelli, M., López-Beltrán, A., Cheng, L., & Montironi, R. (2019) · Future Oncology · doi:10.2217/fon-2019-0217 · Cited by 16
Self-citationCimadamore, A., Scarpelli, M., Santoni, M., Massari, F., Tartari, F., Cerqueti, R., Antonio Lopez-beltran, B., Liang Cheng, C., & Montironi, R. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190225124352 · Cited by 13
Self-citationImmunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
Yu, S. S., Ballas, L., Skinner, E. C., Dorff, T. B., Sadeghi, S., & Quinn, D. I. (2017) · PubMed · Cited by 8
Cited by
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Role of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 442
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308849 · Cited by 340
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Yang, M., Li, S., Li, R., Dong, Y., Zhou, M., Zhao, J., Liu, M., & Tan, R. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.05.006
Metadata
- Authors
- Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Cheng, L., & Montironi, R.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-03
- Volume
- 13
- Issue
- 1
- Pages
- 131
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3118442307
- Cited by
- 279
- References
- 77
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.